Consuelo Mancías-Guerra

Consuelo Mancías-Guerra

Auto-generated profile, based on publicly available information

Consuelo Mancías-Guerra

Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Nuevo León, México

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Cytotherapy
Verified
Journal Article
Closed access
CMConsuelo Mancías-Guerra
Consuelo Mancías-Guerra
AMAlma Rosa Marroquín-Escamilla
Alma Rosa Marroquín-Escamilla
OGOscar González-Llano
Oscar González-Llano
LVLaura Villarreal-Martínez
Laura Villarreal-Martínez
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
DGDavid Gómez-Almaguer
David Gómez-Almaguer

24 August 2016 in Hematology
Verified
Journal Article
Closed access
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
JGJosé Alberto García-Lozano
José Alberto García-Lozano
OTOscar Rubén Treviño-Montemayor
Oscar Rubén Treviño-Montemayor
JIJosé Luis Iglesias-Benavides
José Luis Iglesias-Benavides
OCOlga Graciela Cantú-Rodríguez
Olga Graciela Cantú-Rodríguez
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Objective: To compare serum ferritin (SF) concentrations and other hematological parameters between patients with preeclampsia (PE) and normal pregnant women of the same gestational period who received supplemental iron during pregnancy. Methods: Prospective, comparative, observational pilot study that included 31 women with PE and 30 healthy pregnant women, at 20 weeks’ of gestation. Ferritin, iron and complete blood cell count were compared between groups. Results: In comparison with controls, preeclamptic patients had a higher weight, body mass index, and arterial pressure. Serum ferritin and serum iron were higher in patients with PE (median: 36.5 μg/l vs. 20.9 μg/l and 103.9 μg/dl vs. 90.8 μg/dl) with a significant difference (P = 0.019 and P = 0.345). SF values >40 μg/l correlated with PE (r = 0.281; P = 0.032). A platelet count less than 100 × 109/l was higher in the PE group than in the control group (13% vs. 3%, P = 0.354). Conclusion: Higher SF levels, despite being within normal range, were associated with PE. The incidence of thrombocytopenia was higher in preeclamptic women, however, the remaining hematological parameters were similar in both groups.

21 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OCOlga G. Cantu-Rodriguez
Olga G. Cantu-Rodriguez
JHJose A. Hawing-Zarate
Jose A. Hawing-Zarate
EDEdgar G. Dorsey-Trevino
Edgar G. Dorsey-Trevino
DHDavid Hernandez-Barajas
David Hernandez-Barajas
LVLeonel E. Villalobos-Gutierrez
Leonel E. Villalobos-Gutierrez
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
Background: The lactate/pyruvate (LP) ratio has been studied as an alternative to serum lactate to determine clinical prognosis. Despite its clinical utility, there is a paucity of evidence evaluating the role of the L/P ratio in patients with sepsis. Methods: We assessed the clinical utility of the L/P ratio in patients with sepsis. The L/P ratio was measured at baseline, 4 and 8 h after admission. Our primary outcome was to determine the prognostic utility of the L/P ratio on the 15-day mortality risk. Our secondary outcomes were to compare the L/P ratio across time and its prognostic utility against standard risk calculators such as APACHE-II and SOFA scores. Results: We had a total of 80 patients, with 18 (22.5%) survivors and 62 (77.5%) non-survivors. While we found that patients having higher L/P ratios at 8 h had an increased 30-mortality risk (OR 1.08, 95% CI 1.02–1.18), the model’s performance showed no difference when compared to other measurements of the L/P ratio that showed no association with mortality (p-value: 0.45). For our secondary outcome, we found that the APACHE-II and SOFA scores have better performance and predictability than the L/P ratio (AUC 0.83 and AUC 0.80, respectively), but showed no association with mortality (OR 1.07, 95% CI 1.01–1.17 and OR 1.08, 95% CI 1.02–1.18). Conclusions: Based on our findings, the L/P ratio appears to function more effectively as an early predictor of mortality when used as an adjuvant biomarker with other clinical parameters.

23 April 2020 in Revista Mexicana de Urología
Verified
Journal Article
Open access
PDF file
JRJosé Iván Robles-Torres
José Iván Robles-Torres
CMConsuelo Mancías-Guerra
Consuelo Mancías-Guerra
AGAlejandra Garza-Bedolla
Alejandra Garza-Bedolla
LGLauro Salvador Gómez-Guerra
Lauro Salvador Gómez-Guerra
Clinical case description: A 61-year-old man with severe erectile dysfunction related to diabetes mellitus of long duration was treated through intracavernous stem cell application. Transplantation of autologous bone marrow stem cells through a single intracavernous injection was performed. Clinical response, Doppler ultrasound of the penis, and adverse events were evaluated during the 50-week follow-up. The highest clinical response was reported at week 12, but it diminished thereafter. At the end of follow-up, ultrasound identified the presence of neovascularization emerging from the cavernous arteries. Relevance: Numerous preclinical trials have demonstrated efficacy and safety, but there is insufficient clinical evidence showing promising results. Clinical implications: No adverse events were detected, and ultrasound revealed hemodynamic changes that were possibly related to the therapy. The source and dosage of stem cells, as well as subsequent therapeutic applications, pose questions that remain to be answered. Conclusions: Stem cell therapy for erectile dysfunction is a field of research that has sparked interest in numerous scientific groups, but clinical experience is still limited.

1 January 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
CMConsuelo Mancías-Guerra
Consuelo Mancías-Guerra
SSSandra Abigail Sánchez-García
Sandra Abigail Sánchez-García
SCSofía Alejandra Carreño-Salcedo
Sofía Alejandra Carreño-Salcedo
CGCesar Homero Gutiérrez-Aguirre
Cesar Homero Gutiérrez-Aguirre

1 July 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JCJulia Esther Colunga-Pedraza
Julia Esther Colunga-Pedraza
PCPerla Rocío Colunga-Pedraza
Perla Rocío Colunga-Pedraza
HBHilda Valeria Benavides-López
Hilda Valeria Benavides-López
JMJosé Eduardo Mares-Gil
José Eduardo Mares-Gil
YJYajaira Valentine Jimenez-Antolinez
Yajaira Valentine Jimenez-Antolinez
OGOscar González-Llano
Oscar González-Llano
Intrathecal chemotherapy is a mainstay component of acute lymphoblastic leukemia treatment. In Mexico, there is a considerable practice variability in aspects, such as the manner of preparation and the administration technique. Our objective was to describe the different techniques used for the application of ITC and review the existing recommendations in the literature. A cross-sectional, nationwide survey study was conducted by an electronic questionnaire sent to hematologists and oncologists in Mexico. We collected demographic data, personal experience, intrathecal chemotherapy techniques, drug preparation and postprocedural conduct. We received 173 responses. Twenty percent had an anesthesiologist administering sedation and pain management. The platelet count considered safe was 50 × 109/L in 48% of the participants. In 77% (n = 133) of the cases, the conventional needle with stylet used was, 49% did not receive any added diluent in the intrathecal chemotherapy and only 42% were recommended to rest in a horizontal position for more than 30 min. We identified a considerable variation in the administration of intrathecal chemotherapy across the hematologists in Mexico. We discuss the implications and opportunities in reducing the variation in our setting, highlighting the unmet need to establish guidelines that should be evaluated by the Mexican professional society to produce a position paper regarding practice standardization.